Reagent for accelerating spheroid formation

Kuni-Grow+ ® series

Kuni-Grow+

Kuni-Grow+, developed by Kunimine Industries Co.Ltd., is a reagent for cell culture that composed mainly by inorganic layered compounds (clay). Simply by adding it to your culture medium, it adsorbs growth factors (serum proteins, etc.) in the medium and accelerates the formation of spheroids by acting on cells. Research to date has confirmed spheroid formation in a variety of cancer cell lines. We offer four types of reagents with different mineral species, and we have prepared a trial kit so that you can first select the most suitable reagent for your target cell lines.

Features

  • No special culture media or culture containers are required.
  • Able to store at room temperature.
  • Effectiveness has been confirmed in various cancer cell lines.
  • Spheroid formation is possible in a short time (several days to a week).
  • Observation of time lapse is possible because spheroid formations are distributed throughout the entire culture and do not move much.

Magnified image of spheroid of HT29 cell

  • *Microscopic image
  • *Electron microscope image

How to use

  1. Add Kuni-Grow+ to your culture medium at a ratio of 98(medium):2(reagent) and mix well.
  2. Filter through a syringe filter (5 μm pore size) to remove aggregates.
    Note: This is not mandatory procedure, but is recommended.
  3. Add an equal volume of cell suspension to the culture plate after dispensing, then, start the culture.
    Note: Exchanging culture media is the same method as normal planar culture.

03303_img04R.png

Examples

Example of culture with HT29 cells (after 5 days)

Culture medium:
RPMI-1640, Serum 10% FCS
Plate:
Adherent cell culture plate
Non reagent added
Kuni-Grow+ is added

Overall, spheroid formation was observed after Kuni-Grow+ is added.

Comparison with dedicated medium in U-87MG cells (after 5 days)

Medium:
RPMI-1640, serum 10% FCS
Plate:
Adherent cell culture plate
Used commercially available culture media
Kuni-Grow+ is added

In both cases, spheroids are distributed throughout, but spheroid size is larger when Kuni-Grow+ is added.

Cell lines with proven efficacy (as of March 2024)

Cell type Cell line Origin
Glioblastoma LN-229 Human Glioblastoma
KNS-81 Human Glioblastoma
LN-299 Human Glioblastoma
U-251MG Human Glioblastoma
U-87MG Human Glioblastoma
Kidney Cancer 786-O Human Kidney Cancer
ACHN Human Renal Line Carcinoma
Caki-1 Human Kidney Cancer
Caki-2 Human Kidney Cancer
Colorectal Cancer DLD1 Adenocarcinoma of the Human Colon
HCT 116 Adenocarcinoma of the Human Colon
HT29 Adenocarcinoma of the Human Colon
SW620 Adenocarcinoma of the Human Colon
Pancreatic Cancer AsPC-1 Human Metastatic Pancreatic Adenocarcinoma
KLM-1 Human Pancreatic Cancer
MIA PaCa-2 Human Pancreatic Cancer
PANC-1 Human Pancreatic Adenocarcinoma
Ovarian Cancer A2780 Human Ovarian Cancer
Caov-3 Human Ovarian Cancer
SK-OV-3 Human Ovarian Adenoma
Bladder Cancer 5637 Human Bladder Cancer
UM-UC-3 Human Bladder Cancer
Lung Cancer A549 Human Lung Cancer
Neuroblastoma SH-SY5Y Human Human Neuroblastoma

Lineup

Trial kits (4 types in total, 1mL each) are available, so please select the optimal reagent for your target cell line.

Product code Product Name Volume
192000 Kuni-Grow+_Trial Kit 1mLx4
192010 Kuni-Grow+_B (Blue label) 5mL
192020 Kuni-Grow+_Y (Yellow label) 5mL
192030 Kuni-Grow+_G (Green label) 5mL
192040 Kuni-Grow+_R (Red label) 5mL

Note: Each grade (B, Y, G, R) has different mineral species. Please use according to the compatibility with the culture cell type.

Product List

  • Open All
  • Close All

For research use or further manufacturing use only. Not for use in diagnostic procedures.

Product content may differ from the actual image due to minor specification changes etc.

If the revision of product standards and packaging standards has been made, there is a case where the actual product specifications and images are different.

+49-2131-311-271

Reception hours: Mon-Fri 9:00 - 15:00 (CET)For other hours than the above, please contact us via the inquiry form.